BioAtla (BCAB) Non-Current Assets (2020 - 2026)
BioAtla's (BCAB) quarterly Non-Current Assets came in at -$3.1 million in Q1 2026, down 510.76% year-on-year from $753000.0 in Q1 2025, and up 17.03% quarter-over-quarter from -$3.7 million in Q4 2025.
BioAtla (BCAB) Non-Current Assets (2020 - 2026) Analysis & Trends
BioAtla's Non-Current Assets history runs 7 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 510.76% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was $5.9 million, a 3.06% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, down 413.28% from the prior year.
- Non-Current Assets grew to -$3.1 million in Q1 2026 per BCAB's latest filing, from -$3.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $6.6 million in Q1 2022 and bottomed at -$3.7 million in Q4 2025.
- The 5-year median for Non-Current Assets is $3.9 million (2023), against an average of $3.2 million.
- Across the five-year window, Non-Current Assets soared 273.76% in 2025 and tumbled 510.76% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $5.3 million in 2022, then tumbled by 38.7% to $3.3 million in 2023, then plunged by 63.41% to $1.2 million in 2024, then tumbled by 413.28% to -$3.7 million in 2025, then advanced by 17.03% to -$3.1 million in 2026.
- Per Business Quant, the three latest BCAB Non-Current Assets figures stand at -$3.1 million (Q1 2026), -$3.7 million (Q4 2025), and $6.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | BioAtla | 5.74 Mn | 5.74 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.09 Mn |
| Dec 31, 2025 | -3.73 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 6.52 Mn |
| Mar 31, 2025 | 753,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.77 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 3.85 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Sep 30, 2022 | 5.80 Mn |
| Jun 30, 2022 | 6.30 Mn |
| Mar 31, 2022 | 6.63 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Sep 30, 2021 | 4.06 Mn |
| Jun 30, 2021 | 4.38 Mn |